SPOTLIGHT: Bayer, Onyx seek new Nexavar approval

Bayer and Onyx announced that they have submitted Nexavar to the FDA for approval to treat a common form of liver disease. Researchers are also planning a late-stage study of the cancer drug as an adjuvant treatment of hepatocellular carcinoma following the complete removal of early stage liver cancer. Release